56 results about "3T3 cells" patented technology

The present invention relates to a method for making a three-dimensional cultured skin model comprising a dermis and an epidermis, which comprises: a step of preparing the dermis using a composition comprising a mouse-derived fibroblast, a native collagen or a combination of a native collagen and an atelocollagen; and a step of forming the epidermis using a keratin cell. Also, the present invention relates to a three-dimensional cultured skin model which comprises: a dermis made by a composition comprising a mouse-derived fibroblast, a native collagen, or a combination of a native collagen and an atelocollagen; and an epidermis formed from a keratin cell. The three-dimensionally cultured skin model of the present invention may be used widely in toxicity and efficacy experiments of medicines or cosmetics, and in the field of alternative experiments for animal experiments since the three-dimensionally cultured skin model is excellent in formation and differentiation of a dermis and an epidermis through use of a mouse-derived 3T3 cell for making the skin model and use of a mixture of an atelocollagen and a native collagen, and has a structure similar to a natural skin layer by inhibiting collagen shrinkage and degradation phenomenon of the dermis.

The Rev peptide that binds to nucleophosmin / B23 with the highest affinity exhibits the greatest cytotoxicity on Ras-3T3 cells and inhibits tumor growth most effectively in nude mice. The efficiency of colony formation in soft agar of Ras-3T3 cells is significantly inhibited by treatment with Rev peptide. In addition, Rev peptide can potentiate the doxorubicin-induced decrease of cellular viability in U1 bladder cancer cells and inhibition of tumor growth in nude mice. Treatment of Rev peptide increases protein expression and transcriptional activity of p53 and inhibits the nucleophosmin / B23-mediated PCNA promoter activation. Peptides having high affinity of binding to molecular targets such as nucleophosmin / B23 represent a useful approach to anti-cancer biotherapeutics.

The invention discloses a water soluble mitochondrial targeting imaging probe and a preparation method thereof. The structural formula of compounds that form the water soluble mitochondrial targeting imaging probe can be formula (I), (II), (III), (IV), (V), or (VI). The water soluble mitochondrial targeting imaging probe has the characteristics of good water solubility, high resistance to photo-bleaching, high thermal stability, low toxicity, and high sensitivity. Hela, MCF-7, and NIH-3T3 cells are taken as the models to observe the distribution situation of the fluorescent probe in cells through a laser con-focal microscopy technology; the results show that the probe is mainly distributed in mitochondrial, and the targeting property is good. The test results show that the provided probe has the characteristic of strong mitochondrial targeting imaging performance on cancer cells and non-cancer cells; thus an effective means is provided for quantitatively research superoxide radicals in cells in time and space, and thus the pathologic and physiological mechanisms of active oxygen radicals can be researched.

Targeting metabolic enzymes in human cancer Abstract Lung cancer is a devastating disease and a major therapeutic burden with poor prognosis. The functional heterogeneity of lung cancer (different tumor formation ability in bulk of tumor) is highly related with clinical chemoresistance and relapse. Here we find that, glycine dehydrogenase (GLDC), one of the metabolic enzyme involved in glycine metabolism, is overexpressed in various subtypes of human lung cancer and possibly several other types of cancers. GLDC was found to be highly expressed in tumor-initiating subpopulation of human lung cancer cells compared with non-tumorigenic subpopulation. By array studies we showed that normal lung cells express low levels of GLDC compared to xenograft and primary tumor. Functional studies showed that RNAi inhibition of GLDC inhibits significantly the clonal growth of tumor-initiating cells in vitro and tumor formation in immunodeficient mice. Overexpression of GLDC in non-tumorigenic subpopulation convert the cells to become tumorigenic. Furthermore, over-expression of GLDC in NIH / 3T3 cells and human primary lung fibroblasts can transform these cells, displaying anchorage-independent growth in soft agar and tumor-forming in mice. Not only is GLDC is expressed human lung cancer, it is also up-regulated in other types of cancer, such as colon cancer. RNAi knockdown of GLDC in colon cancer cell line, CACO-2 cells, can also inhibit the tumor formation in mice. Thus GLDC maybe a new metabolic target for treatment of lung cancer, and other cancers.

The present invention discloses a new kind of human protein with the functions of promoting 3T3 cell transformation, polynucleotides encoding this polypeptide and recombination process to produce the polypeptide. The present invention also discloses the agonist resisting the polypeptide and its treatment effect. The present invention also discloses the application of the polynucleotides encoding this new kind of human protein with the functions of promoting 3T3 cell transformation.